HomeCompareCLVLF vs O

CLVLF vs O: Dividend Comparison 2026

CLVLF yields 0.39% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLF wins by $316.1K in total portfolio value· pulled ahead in Year 4
10 years
CLVLF
CLVLF
● Live price
0.39%
Share price
$8.45
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.4K
Annual income
$233,845.04
Full CLVLF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — CLVLF vs O

📍 CLVLF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLF
Annual income on $10K today (after 15% tax)
$32.77/yr
After 10yr DRIP, annual income (after tax)
$198,768.28/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, CLVLF beats the other by $194,430.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLF + O for your $10,000?

CLVLF: 50%O: 50%
100% O50/50100% CLVLF
Portfolio after 10yr
$192.3K
Annual income
$119,473.89/yr
Blended yield
62.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

CLVLF
No analyst data
Altman Z
21.3
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLF buys
0
O buys
0
No recent congressional trades found for CLVLF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLFO
Forward yield0.39%5.28%
Annual dividend / share$0.03$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.1%
Portfolio after 10y$350.4K$34.2K
Annual income after 10y$233,845.04$5,102.74
Total dividends collected$320.5K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CLVLF vs O ($10,000, DRIP)

YearCLVLF PortfolioCLVLF Income/yrO PortfolioO Income/yrGap
1$10,777$77.10$10,818$608.16$41.00O
2$11,687$155.31$11,787$741.68$100.00O
3$12,820$314.80$12,946$911.00$126.00O
4← crossover$14,363$645.46$14,345$1,127.94+$18.00CLVLF
5$16,720$1,351.66$16,056$1,409.05+$664.00CLVLF
6$20,831$2,941.08$18,171$1,777.83+$2.7KCLVLF
7$29,138$6,849.18$20,820$2,268.21+$8.3KCLVLF
8$49,086$17,907.69$24,188$2,929.90+$24.9KCLVLF
9$108,908$56,386.61$28,533$3,837.11+$80.4KCLVLF
10$350,377$233,845.04$34,235$5,102.74+$316.1KCLVLF

CLVLF vs O: Complete Analysis 2026

CLVLFStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this CLVLF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLF vs SCHDCLVLF vs JEPICLVLF vs KOCLVLF vs MAINCLVLF vs STAGCLVLF vs ADCCLVLF vs NNNCLVLF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.